Gene therapy for osteoarthritis

Flexion Therapeutics Announces Presentation of Preliminary FX201 Clinical Data at the Upcoming 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Wednesday, April 28, 2021
Clinical medicine, Medicine, Medical specialties, Skeletal disorders, Arthritis, Rheumatology, Osteoarthritis, Forward-looking statement, XC2, Cohort, Gene therapy for osteoarthritis

We look forward to providing updated data from this cohort at ASGCT on May\xc2\xa011.\xe2\x80\x9d\nThe clinical data will be presented in a digital presentation entitled, Interim Data from the First-in-Human Phase 1 Trial of FX201, An Intra-Articular, Helper-Dependent Adenoviral Gene Therapy for Osteoarthritis - Safety, Tolerability, Biodistribution, and Preliminary Evaluation of Clinical Activity in 5 Patients ( Abstract 594 ).

Key Points: 
  • We look forward to providing updated data from this cohort at ASGCT on May\xc2\xa011.\xe2\x80\x9d\nThe clinical data will be presented in a digital presentation entitled, Interim Data from the First-in-Human Phase 1 Trial of FX201, An Intra-Articular, Helper-Dependent Adenoviral Gene Therapy for Osteoarthritis - Safety, Tolerability, Biodistribution, and Preliminary Evaluation of Clinical Activity in 5 Patients ( Abstract 594 ).
  • The company's core values are focus, ingenuity, tenacity, transparency, and fun.
  • Please visit flexiontherapeutics.com .\nThis press release contains forward-looking statements that are based on the current expectations and beliefs of Flexion.
  • We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.\n"

Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapies

Retrieved on: 
Tuesday, March 30, 2021
Branches of biology, Life sciences, Biology, Biotechnology, Applied genetics, Molecular biology, Medical genetics, Emerging technologies, Gene therapy, Therapy, Gene therapy for osteoarthritis

The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in 2019, and is expected to reach $375.13 thousand by 2030, registering a CAGR of 16.61% during the forecast.

Key Points: 
  • The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in 2019, and is expected to reach $375.13 thousand by 2030, registering a CAGR of 16.61% during the forecast.
  • Cell and gene therapy drug delivery industry is a transformative industry whose full potential is only just beginning to emerge.
  • Cell and gene therapy involves the extraction of cells, protein, or genetic material (DNA) from the donor, and altering them to provide highly personalized therapy.
  • One of the significant drugs of the cell and gene therapy industry is CAR-T cell-based medicines, which include both cell therapy and gene therapy.

TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage

Retrieved on: 
Monday, May 18, 2020
Medicine, Medical specialties, Health, RTT, Skeletal disorders, Arthritis, Osteoarthritis, Cartilage, Gene therapy for osteoarthritis

These findings were accepted as an abstract at Osteoarthritis Research Society International (OARSI) 2020 and published in the Osteoarthritis and Cartilage journal ( #722 ).

Key Points: 
  • These findings were accepted as an abstract at Osteoarthritis Research Society International (OARSI) 2020 and published in the Osteoarthritis and Cartilage journal ( #722 ).
  • We are happy to see that results of the subgroup analyses are consistent with our primary efficacy data, said George Yeh, President of TLC.
  • Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins.
  • An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments.

Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis

Retrieved on: 
Thursday, October 31, 2019
Branches of biology, Interleukins, Cytokines, Medical specialties, Medicine, Interleukin-1 family, Interleukin 1 receptor antagonist, Inflammation, Gene therapy for osteoarthritis

FX201 is a helper-dependent non-integrating adenovirus containing the human interleukin-1 receptor antagonist (IL-1Ra) gene under the control of an inflammation sensitive promoter.

Key Points: 
  • FX201 is a helper-dependent non-integrating adenovirus containing the human interleukin-1 receptor antagonist (IL-1Ra) gene under the control of an inflammation sensitive promoter.
  • Preclinical data show that gene expression persists for at least one year, and IL-1Ra expression increases in response to inflammation.
  • The appointments to Flexion's Gene Therapy SAB include:
    Robert Kotin, PhD is the Scientific founder of Generation Bio.
  • Philip Reilly, MD, JD is a physician geneticist who helped found Bluebird bio and Voyager Therapeutics, two gene therapy companies that are publicly traded.

Worldwide Gene Therapy Markets, 2014 to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 12, 2019
Professional services, Consulting, Branches of biology, Biology, Life sciences, Applied genetics, Biotechnology, Medical genetics, Gene delivery, Molecular biology, Gene therapy, Therapy, Gene therapy for osteoarthritis

The study has segmented the global gene therapy market report on the basis of indication, vector, and region.

Key Points: 
  • The study has segmented the global gene therapy market report on the basis of indication, vector, and region.
  • Gene therapy involves modification of the faulty and missing gene/s and then delivery to the intended target using modified viral particles or other bio-technologically approved methods.
  • Gene therapy, once considered impossible on a commercial-scale has now become a trend and most of the companies are banking on breakthrough innovations in the field.
  • For instance, more than 60% of the gene therapy pipeline is being tested for oncological treatments.

Global Gene Therapy Market, 2019-2026: Size, Share & Trends Analysis & Forecast by Vector, Indication, and Region

Retrieved on: 
Monday, August 12, 2019
Branches of biology, Biology, Life sciences, Applied genetics, Biotechnology, Molecular biology, Gene delivery, Medical genetics, Gene therapy, Virus, Gene therapy for osteoarthritis, Vectors in gene therapy

The study has segmented the global gene therapy market report on the basis of indication, vector, and region.

Key Points: 
  • The study has segmented the global gene therapy market report on the basis of indication, vector, and region.
  • Gene therapy involves modification of the faulty and missing gene/s and then delivery to the intended target using modified viral particles or other bio-technologically approved methods.
  • Gene therapy, once considered impossible on a commercial-scale has now become a trend and most of the companies are banking on breakthrough innovations in the field.
  • Many of the smaller companies have been successful in bringing few molecules to the market with the backing of larger companies.

Gene Therapy Market Growth to be Driven by Increased Commercialization In Developed Countries: Radiant Insights, Inc.

Retrieved on: 
Tuesday, February 5, 2019
Biology, Gene delivery, Genetics, Applied genetics, Bioethics, Molecular biology, Genetic engineering, Gene therapy, Viral vector, Therapy, Gene therapy for osteoarthritis

The factors that are playing a major role in the growth of Gene Therapy Market are growing occurrence of life-threatening and chronic disorders, increasing concentration to accelerate commercialization of gene therapy in developed nations.

Key Points: 
  • The factors that are playing a major role in the growth of Gene Therapy Market are growing occurrence of life-threatening and chronic disorders, increasing concentration to accelerate commercialization of gene therapy in developed nations.
  • Gene Therapy Market is segmented based on vectors type, approved gene therapy, application, and region.
  • Non-viral vectors and viral vectors are the vector's type that could be explored in Gene Therapy in the forecast period.
  • Access 205 page research report with TOC on "Gene Therapy Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-and-us-gene-therapy-mark...
    The major part of the revenue of gene therapy market is generated from research phase.

Gene Therapy Market Growth to be Driven by Increased Commercialization In Developed Countries: Radiant Insights, Inc.

Retrieved on: 
Tuesday, February 5, 2019
Branches of biology, Biology, Life sciences, Gene delivery, Applied genetics, Bioethics, Emerging technologies, Molecular biology, Gene therapy, Viral vector, Therapy, Gene therapy for osteoarthritis

The factors that are playing a major role in the growth of Gene Therapy Market are growing occurrence of life-threatening and chronic disorders, increasing concentration to accelerate commercialization of gene therapy in developed nations.

Key Points: 
  • The factors that are playing a major role in the growth of Gene Therapy Market are growing occurrence of life-threatening and chronic disorders, increasing concentration to accelerate commercialization of gene therapy in developed nations.
  • Gene Therapy Market is segmented based on vectors type, approved gene therapy, application, and region.
  • Non-viral vectors and viral vectors are the vector's type that could be explored in Gene Therapy in the forecast period.
  • Access 205 page research report with TOC on "Gene Therapy Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-and-us-gene-therapy-mark...
    The major part of the revenue of gene therapy market is generated from research phase.

Global Gene Therapy Epidemiology 2017-2027: Focus on Technologies, Markets and Companies

Retrieved on: 
Wednesday, July 25, 2018
Biology, Biotechnology, Molecular biology, Applied genetics, Gene delivery, Emerging technologies, Gene therapy, Viral vector, Therapy, Genetic engineering, Gene therapy for osteoarthritis, Vectors in gene therapy

This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies.

Key Points: 
  • This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies.
  • This report describes the setbacks of gene therapy and renewed interest in the topic
    Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors.
  • Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described.
  • The markets for gene therapy have been difficult to estimate as there only a few approved gene therapy products Gene therapy markets are estimated for the years 2017-2027.

Mundipharma Extends Strategic Partnership with Kolon Life Science to Commercialise Invossa(R)-k in Saudi Arabia and United Arab Emirates

Retrieved on: 
Tuesday, June 26, 2018
Biology, Health, Medicine, Arthritis, Osteoarthritis, RTT, Therapy, Gene therapy for osteoarthritis, Gene therapy

SINGAPORE, June 26, 2018 /PRNewswire/ -- Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to marketInvossa-K in Saudi Arabia and United Arab Emirates.

Key Points: 
  • SINGAPORE, June 26, 2018 /PRNewswire/ -- Mundipharma has announced the extension of its strategic partnership with Kolon Life Science to marketInvossa-K in Saudi Arabia and United Arab Emirates.
  • The agreement builds on the existing co-promotion agreement between the two companies in Korea signed in April 2017.
  • "We are delighted to extend our relationship with Kolon Life Science and Invossa-Kinternationally," said Raman Singh, CEO, Mundipharma.
  • Kolon Life Science has been developing innovative cell and gene therapies including Invossa-K the world's first cell-mediated gene therapy for osteoarthritis, since its founding in 2000.